Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Wei Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3233-8877; OpenAlex author ID A5100344573. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. An MOF-Enhanced Anti-Fouling Immunoprobe Platform for Efficient Direct Screening of Pancreatic Cancer. Co-author DOI 10.1002/advs.202503619↗
  2. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Co-author DOI 10.1016/j.biomaterials.2018.11.035↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenjuan Yang · 1 shared paper, 2025 · strength 0.24
  2. Yuan Zhang · 1 shared paper, 2025 · strength 0.24
  3. Xiao Zhi · 1 shared paper, 2019 · strength 0.09
  4. Bin Zhao · 1 shared paper, 2019 · strength 0.09
  5. Tao Ma · 1 shared paper, 2019 · strength 0.09
  6. Hao Liu · 1 shared paper, 2019 · strength 0.09
  7. Tingbo Liang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.